The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Chemotherapy‐induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death
Open accessAbstract
Certain chemotherapeutic regimens trigger cancer cell death while inducing dendritic cell maturation and subsequent immune responses. However, chemotherapy‐induced immunogenic cell death (ICD) has thus far been restricted to select agents. In contrast, several chemotherapeutic drugs modulate antitumor immune responses, despite not inducing classic ICD. In addition, in many cases tumor cells do not die after treatment. Here, using docetaxel, one of the most widely used cancer chemotherapeutic agents, as a model, we examined phenotypic and functional consequences of tumor cells that do not die from ICD. Docetaxel treatment of tumor cells did not induce ATP or high‐mobility group box 1 (HMGB1) secretion, or cell death. However, calreticulin (CRT) exposure was observed in all cell lines examined after chemotherapy treatment. Killing by carcinoembryonic antigen (CEA), MUC‐1, or PSA‐specific CD8+CTLs was significantly enhanced after docetaxel treatment. This killing was associated with increases in components of antigen‐processing machinery, and mediated largely by CRT membrane translocation, as determined by functional knockdown of CRT, PERK, or CRT‐blocking peptide. A docetaxel‐resistant cell line was selected (MDR‐1+, CD133+) by continuous exposure to docetaxel. These cells, while resistant to direct cytostatic effects of docetaxel, were not resistant to the chemomodulatory effects that resulted in enhancement of CTL killing. Here, we provide an operational definition of “immunogenic modulation,” where exposure of tumor cells to nonlethal/sublethal doses of chemotherapy alters tumor phenotype to render the tumor more sensitive to CTL killing. These observations are distinct and complementary to ICD and highlight a mechanism whereby chemotherapy can be used in combination with immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death
Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
Garg, A. D., Krysko, D. V., Verfaillie, T., Kaczmarek, A., Ferreira, G. B., Marysael, T., Rubio, N., Firczuk, M., Mathieu, C., Roebroek, A. J. M., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.497 · Cited by 800
Chao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., Weiskopf, K., Willingham, S. B., Raveh, T., Park, C. Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001375 · Cited by 776
Immune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 669
Luo, B., & Lee, A. S. (2013) · Oncogene · doi:10.1038/onc.2012.130 · Cited by 560
Garnett, C. T., Palena, C., Chakarborty, M., Tsang, K.-Y., Schlom, J., & Hodge, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1525 · Cited by 557
Self-citationTsang, K. Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M., & Schlom, J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.13.982 · Cited by 498
Self-citationAntigen-processing machinery breakdown and tumor growth
Seliger, B., Maeurer, M. J., & Ferrone, S. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01692-3 · Cited by 459
Self-citationMartins, I., Kepp, O., Schlemmer, F., Adjemian, S., Tailler, M., Shen, S., Michaud, M., Menger, L., Gdoura, A., Tajeddine, N., et al. (2011) · Oncogene · doi:10.1038/onc.2010.500 · Cited by 414
Drug resistance in cancer: Principles of emergence and prevention
Komarova, N. L., & Wodarz, D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501870102 · Cited by 414
Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway
Zitvogel, L., Kepp, O., Senovilla, L., Menger, L., Chaput, N., & Kroemer, G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2891 · Cited by 387
The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death
Panaretakis, T., Joza, N., Modjtahedi, N., Tesniere, A., Vitale, I., Durchschlag, M., Fimia, G. M., Kepp, O., Piacentini, M., Froehlich, K.-U., et al. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.67 · Cited by 344
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Kepp, O., Galluzzi, L., Martins, I., Schlemmer, F., Adjemian, S., Michaud, M., Sukkurwala, A. Q., Menger, L., Zitvogel, L., & Kroemer, G. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9273-4 · Cited by 297
Arlen, P. M., Gulley, J. L., Parker, C., Skarupa, L., Pazdur, M., Panicali, D., Beetham, P., Tsang, K. Y., Grosenbach, D. W., Feldman, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2059 · Cited by 287
Self-citationDocetaxel induces cell death through mitotic catastrophe in human breast cancer cells
Morse, D. L., Gray, H., Payne, C. M., & Gillies, R. J. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0130 · Cited by 283
Chemotherapy induces ATP release from tumor cells
Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Séror, C., Métivier, D., Perfettini, J.-L., Zitvogel, L., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.22.10026 · Cited by 278
Trial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Senovilla, L., Eggermont, A., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23510 · Cited by 265
Garnett, C. T., Schlom, J., & Hodge, J. W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4025 · Cited by 232
Self-citationEpigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors
Setiadi, A. F., Omilusik, K., David, M. D., Seipp, R. P., Hartikainen, J., Gopaul, R., Choi, K. B., & Jefferies, W. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5270 · Cited by 184
Cavallo, F., Giovarelli, M., Forni, G., Signorelli, P., Musiani, P., Modesti, A., Brunda, M. J., & Colombo, M. P. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.14.1049 · Cited by 171
López‐Albaitero, A., Nayak, J. V., Ogino, T., Machandia, A., Gooding, W. E., DeLeo, A. B., Ferrone, S., & Ferris, R. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3402 · Cited by 156
Self-citationThe immunological effects of taxanes
Chan, O. T. M., & Yang, L. (2000) · Cancer Immunology Immunotherapy · doi:10.1007/s002620000122 · Cited by 145
On the definition of a criterion of immunogenicity
Pradeu, T., & Carosella, E. D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608683103 · Cited by 133
Trial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Galluzzi, L., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.1.2.19026 · Cited by 132
Surface‐exposed calreticulin in the interaction between dying cells and phagocytes
Martins, I., Kepp, O., Galluzzi, L., Senovilla, L., Schlemmer, F., Adjemian, S., Menger, L., Michaud, M., Zitvogel, L., & Kroemer, G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05740.x · Cited by 123
Microtubule Targeting Agents: Basic Mechanisms of Multidrug Resistance (MDR)
Fojo, A. T., & Menefee, M. E. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.010 · Cited by 123
Leibowitz, M. S., Filho, P. A. A., Ferrone, S., & Ferris, R. L. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0961-7 · Cited by 106
Self-citationSeliger, B., Stoehr, R., Handke, D., Müeller, A., Ferrone, S., Wullich, B., Tannapfel, A., Hofstaedter, F., & Hartmann, A. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0769-5 · Cited by 100
Self-citationPrerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy
Hannani, D., Sistigu, A., Kepp, O., Galluzzi, L., Kroemer, G., & Zitvogel, L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325d4d · Cited by 91
Gelbard, A. H., Garnett‐Benson, C., Abrams, S. I., Patel, V., Gutkind, J. S., Palena, C., Tsang, K.-Y., Schlom, J., & Hodge, J. W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1761 · Cited by 87
Self-citationHuerta, S., Heinzerling, J. H., Hernández, Y. M. A., Huerta‐Yépez, S., Lin, J., Chen, D. J., Bonavida, B., & Livingston, E. H. (2007) · Journal of Surgical Research · doi:10.1016/j.jss.2006.12.551 · Cited by 85
Desirable cell death during anticancer chemotherapy
Locher, C., Conforti, R., Aymeric, L., Ma, Y., Yamazaki, T., Rusakiewicz, S., Tesnière, A., Ghiringhelli, F., Apétoh, L., Morel, Y., et al. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05763.x · Cited by 84
Li, S. S., Liu, Z., Uzunel, M., & Sundqvist, K. (2006) · Blood · doi:10.1182/blood-2006-04-016832 · Cited by 80
Racanelli, V., Leone, P., Frassanito, M. A., Brunetti, C., Perosa, F., Ferrone, S., & Dammacco, F. (2009) · Blood · doi:10.1182/blood-2009-06-228676 · Cited by 79
Self-citationGameiro, S. R., Caballero, J. A., Higgins, J. P., Apelian, D., & Hodge, J. W. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1020-8 · Cited by 77
Self-citationReduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells
Brown, I. M., Shalli, K., McDonald, S. L., Moir, S. E., Hutcheon, A. W., Heys, S. D., & Schofield, A. C. (2004) · Breast Cancer Research · doi:10.1186/bcr918 · Cited by 76
Bandoh, N., Ogino, T., Cho, H. S., Hur, S. Y., Shen, J., Wang, X., Kato, S., Miyokawa, N., Harabuchi, Y., & Ferrone, S. (2005) · Tissue Antigens · doi:10.1111/j.1399-0039.2005.00462.x · Cited by 71
Self-citationMatsuzaki, I., Suzuki, H., Kitamura, M., Minamiya, Y., Kawai, H., & Ogawa, J. (2000) · Oncology · doi:10.1159/000012192 · Cited by 51
Paradigm Shifts in Cancer Vaccine Therapy
Schlom, J., Gulley, J. L., & Arlen, P. M. (2008) · Experimental Biology and Medicine · doi:10.3181/0708-mr-226 · Cited by 48
Immunological effects of Taxol and Adryamicin in breast cancer patients
Panis, C., Lemos, L. G. T., Victorino, V. J., Herrera, A. C. S. A., de Campos, F. C., Simão, A. N. C., Pinge‐Filho, P., Cecchini, A. L., & Cecchini, R. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1117-0 · Cited by 45
Minami, H., Kawada, K., Sasaki, Y., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.00992.x · Cited by 44
Shtil, A. A., Turner, J. G., Durfee, J., Dalton, W. S., & Yu, H. (1999) · Blood · doi:10.1182/blood.v93.6.1831.406k38_1831_1837 · Cited by 42
Characteristics of CD133 + Human Colon Cancer SW620 Cells
Kawamoto, H., Yuasa, T., Kubota, Y., Seita, M., Sasamoto, H., Shahid, J. M., Hayashi, T., Nakahara, H., Hassan, R. A. R. A., Iwamuro, M., et al. (2010) · Cell Transplantation · doi:10.3727/096368910x508988 · Cited by 39
Calreticulin maintains the low threshold of peptide required for efficient antigen presentation
Fu, H., Liu, C., Flutter, B. R., Tao, H., & Gao, B. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.08.012 · Cited by 13
Cited by
Immune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Emens, L. A., & Middleton, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0064 · Cited by 831
Cornel, A. M., Mimpen, I. L., & Nierkens, S. (2020) · Cancers · doi:10.3390/cancers12071760 · Cited by 464
Gameiro, S. R., Jammeh, M. L., Wattenberg, M. M., Tsang, K. Y., Ferrone, S., & Hodge, J. W. (2014) · Oncotarget · doi:10.18632/oncotarget.1719 · Cited by 415
Self-citation
Metadata
- Authors
- Hodge, J. W., Garnett, C. T., Farsaci, B., Palena, C., Tsang, K., Ferrone, S., & Gameiro, S. R.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2013-03-16
- Volume
- 133
- Issue
- 3
- Pages
- 624-636
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1480342889
- Cited by
- 281
- References
- 45
- FWCI
- 10.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.